



When men begin androgen deprivation therapy for prostate cancer, they become susceptible to osteoporosis and bone fractures. Egerdie and Saad review the existing and future management options for these patients. See page **129** for more.

Lorsque les hommes commencent une thérapie de privation d'androgène pour le cancer de la prostate, ils deviennent susceptibles à l'ostéoporose et aux fractures osseuses. Egerdie et Saad passent en revue les options de prise en charge actuelles et futures de ces patients. Veuillez vous reporter à la page **129** pour plus de détails.

All editorial matter in *CUAJ* represents the opinions of the authors and not necessarily those of the Canadian Urological Association. The CUA assumes no responsibility or liability for damages arising from any error or omission or from the use of any information or advice contained in *CUAJ*.

Publications Mail Agreement no. 41614530. Return undeliverable Canadian copies to *CUAJ*, 1155 University Ave., Suite 1303, Montréal QC H3B 3A7; journal@cua.org.

Numéro de convention poste-publications 41614530. Retourner toutes copies canadiennes non livrées au *JAUC*, 1155 rue Université, Bureau 1303, Montréal QC H3B 3A7; journal@cua.org.

ISSN 1911-6470
e-ISSN 1920-1214

EDITORIAL

- 83 EBM in Canadian urology**
L. Klotz, Editor-in-chief

ÉDITORIAL

- 84 La MFP dans l'urologie canadienne**
L. Klotz, Rédacteur en chef

CUA NEWS

- 87 Quantifying CUA's progress**
J.B. Gajewski

NOUVELLES DE L'AUC

- 88 Quantifier le progrès de l'AUC**
J.B. Gajewski

CUA GUIDELINES

- 89 CUA guidelines on prostate biopsy methodology**
A. El-Hakim, S. Moussa
- 95 Multicystic dysplastic kidney in the neonate: the role of the urologist**
K. Psooy and the Pediatric Urologists of Canada
- 98 Guidelines on the management of renal cyst disease**
T.F. Whelan

ORIGINAL RESEARCH

- 100 The 20-core prostate biopsy as an initial strategy: impact on the detection of prostatic cancer**
M.A. Jradi, M. Dridi, M. Teyeb, M. Ould Sidi Mohamed, R. Khiary, S. Ghozzi, N. Ben Rais

ORIGINAL RESEARCH

- 105 Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer**
M. Sia, G. Rodrigues, C. Menard, A. Bayley, R. Bristow, P. Chung, M. Gospodarowicz, M. Milosevic, P. Warde, C. Catton

COMMENTARY

- 112** Shared responsibility for treatment-related morbidity for prostate cancer
J.L. Chin, G. Bauman

ORIGINAL RESEARCH

- 114** The status of evidence-based medicine education in urology residency
K. Roth, D.R. Siemens

COMMENTARY

- 121** The teaching of critical appraisal skills in urology residency: What is the evidence?
A.E. MacNeily

ORIGINAL RESEARCH

- 123** The aging male population and medical care for benign prostatic hyperplasia in Canada
N.S.B. Rawson, F. Saad

COMMENTARY

- 127** Do more BPH patients mean more urologists or just better management strategies?
J.C. Nickel

REVIEW

- 128** Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options
B. Egerdie, F. Saad

POINT/COUNTERPOINT

- 136** Active surveillance as the preferred management option for small renal masses
R.A. Rendon

- 139** Preferred management option for small renal masses: laparoscopic partial nephrectomy
A. Kapoor

148 IN MEMORIAM

RESOURCES

- 79** Prescribing Index
86 Listing of online-only articles
144 Urology Meetings of Interest
147 Calendar of CME Events

ONLY ON CUAJ.CA

- Consensus Guideline: Testicular germ cell cancer
 - Case reports
- Instructions for Authors
- Instructions aux auteurs

ADVERTISERS' INDEX / INDEX DES ANNONCEURS

AMS Canada Inc.
78
Astellas Pharma Canada, Inc.
Vesicare, 82, PI 142-3

Pfizer Inc.
Sutent, Outside back cover
Viagra, Inside back cover